US and French medical imaging firms join

By Kirsty Barnes

- Last updated on GMT

Related tags Medical imaging Medicine

Bio-Imaging Technologies has bought French imaging firm Theralys as
it strives to broaden its clinical trial medical imaging service

The primary appeal of Theralys was its experience in the field of central nervous system (CNS) and neurovascular imaging, which US-based Bio-Imaging has been wanting to add to its current areas of oncology, musculoskeletal and cardiovascular imaging, Mark Weinstein, president and CEO of Bio-Imaging told

Specifically, Theralys, based in Lyon, France, operates an imaging core lab that enables the automated quantitation of various imaging parameters such as brain, white matter lesion and hippocampal volumes, MRI diffusion and perfusion.

"In addition, Theralys not only provides us with access to a new geographic area, but is a regional player, and we are on the look out for regional imaging firms that are complimentary to our business that we can turn into global players,"​ said Weinstein.

The two firms, which have already worked together in the past, are in the business of facilitating the use of medical imaging techniques on various part of the body, such as medical resonance imaging (MRI), X-ray, ultrasound etc, at a sponsor company's clinical trial site, as well as organising centralised blinded image reading and analysis services on a contract basis.

Since 2000 the use of such imaging in phase II-IV trials across a range of therapeutic areas for the evaluation of response to therapy and/or indicators of disease progression over time has been actively encouraged by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) is also moving in this direction.

10-15 per cent of studies in the US currently require such imagaing, according to Weinstein.

At the same time however, the regulatory authorities are insisting on the images for each trial being reviewed centrally by an independent third party radiographer in order to minimise variability of result interpretation.

As a result, biopharma companies are increasingly relying on the relatively few contract organisations that supply such services - there are currently three to four global players.

"This area of clinical research is a young industry and is growing well. Currently the overall clinical research organisation (CRO) industry is growing at about 12 per cent however the contract imaging market is growing at between 15 and 20 per cent,"​ said Weinstein.

"In addition, this particular sector has a high barrier to entry and there have been no new entrants of late because pharmaceutical firms want to deal with companies that have experience. This is good news for those of us already well established."

Related news

Related products

show more

The Right CDMO Can Unlock Faster Drug Development

The Right CDMO Can Unlock Faster Drug Development

Content provided by Lonza Small Molecules | 15-May-2023 | Interview

Drug development presents biotech companies with ever-changing challenges. Enabling a faster end-to-end process requires seamless flexibility and extensive...

SDTM supplemental qualifiers explained

SDTM supplemental qualifiers explained

Content provided by Formedix | 12-May-2023 | White Paper

What are SDTM supplemental qualifiers? In short, these are variables in non-CDISC datasets that cannot be mapped to a variable that matches the SDTM standard....

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 25-Apr-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Related suppliers

Follow us


View more